



A REVIEW ARTICLE ON THE EFFECT & ADR OF VACCINE AFTER COVID-19

¹DIKSHITA PATIL , ²GAURAV SONAWANE, ³ISHWAR KOLHE

1miss. Dikshita Patil, 2prof. Gaurav Sonawane, 3ishwar Kolhe

Department Of Pharmacy,

Matoshri Institute Of Pharmacy Dhanore, Yeola, Nashik, Maharashtra, India

abstract: an era of sars-covid-19 outbreak with a high contagious percentage around the globe has been the subject of multi-agency research aimed at generating vaccines for active immunization. scientists across the world are joining hands for advanced tie-ups between medical start-ups and pharmaceutical industries for devices and vaccines development to hinder the progress of this outbreak. the novel coronavirus, sars-cov-2, which causes covid-19, has resulted in a pandemic with millions of deaths. to eradicate sars-cov-2 and prevent further infections, many vaccine candidates have been developed. these vaccines include not only traditional subunit vaccines and attenuated or inactivated viral vaccines but also nucleic acid and viral vector vaccines. in contrast to the diversity in the platform technology, the delivery of vaccines is limited to intramuscular vaccination. although intramuscular vaccination is safe and effective, mucosal vaccination could improve the local immune responses that block the spread of pathogens.

keywords:- covid19, vaccine, efficacy, adr, immune response, acceptance, hesitation, and rejection

I. INTRODUCTION


coronavirus is a single-stranded virus that infects humans and a variety of animals. it belongs to the coronaviridae family.¹ the covid-19 epidemic is spreading at a breakneck pace throughout the world.² in december 2019, a pandemic known as sarscovid-19 broke out in numerous places throughout the world. ^{1,3}it startled the globe into stillness and pushed minds to figure out how to combat the pandemic¹ because no treatment for the virus had been identified, the authorities collectively agreed to establish a lockdown to maximize social separation.⁴ many organizations from both the public and business sectors were impacted. sarscov2 is spreading from china to other nations.⁵ sarscovid19 cases first occurred in the chinese city of wuhan at the end of 2019, and by april 15, 2020, fewer than 1.9 million sarscovid19 cases had been documented worldwide, with approximately 120 000 verified fatalities.⁵ based on the rapidly growing incidence of covid19 in chinese and worldwide locales, who designated this a global health pandemic on january 30, 2020. ¹ covid19 symptoms include loss of taste and smell, coughing, illness, lethargy, fever, and lack of appetite.⁶ it spreads by contact and respiratory droplets, but there should be no doubt regarding airborne, fecal, or intrauterine transmission. ^{7,8}

infection can occur by inhaling small airborne droplets, direct contact with infected people or contaminated surfaces, or larger respiratory droplets⁹ nasal as a diagnostic approach, nasal swabs, tracheal aspirate, or bronchoalveolar lavage samples are used in a real-time polymerase chain reaction.¹⁰ several in-house and commercially accessible assays for detecting the covid19 are being developed at the moment. some tests identify just the specific virus, but others (for example, sars-cov) detect additional genetically identical viruses.¹¹ even though no particular cure for covid-19 has been developed after 10 months of the pandemic, certain possible medicines have shown promising outcomes.¹² during covid19, the most popular preventative measures were social isolation, the use of disinfecting substances such as bleach, quarantine, the use of n95 face masks, and so on. ¹² most healthcare employees are at high risk of covid19 exposure, both the workplace, such as laboratories, in hospital crises, and the community when giving care to patients. patients from covid19.¹³ furthermore, they gain herd immunity through natural immunity, and infections are conceivable, with disastrous results and a high death rate. ^{4,14} this strategy was used in sweden, where authorities assumed that the infection rate was up to 60% of the population, and that herd immunity would be enough to safeguard the population.¹⁵ however, they failed, and covid-19 is responsible for at least five fatalities per million people in sweden.

the different types of vaccine:-

their distinctions include whether they employ the entire virus or bacterium, just the sections of the germ that stimulate the immune system, or simply the genetic information that provides instructions for creating certain proteins rather than the entire virus.

The whole-microbe approach



1. inactivated vaccine:-

the first step in creating a vaccine is to inactivate or kill the disease-carrying virus or bacteria, or one that is substantially similar to it, using chemicals, heat, or radiation. this strategy employs technology that is effective in humans - this is how flu and polio vaccinations are produced - and vaccines can be produced on a reasonable volume. however, it takes sophisticated laboratory equipment to safely cultivate the virus or bacteria, can take a relatively long time to produce, and will almost certainly require two or three doses to be delivered.

2. live attenuated vaccine:-

a live-attenuated vaccination employs a living but weakened virus or one that is substantially similar. this type of vaccination includes the measles, mumps, and rubella (mmr) vaccine as well as the chickenpox and shingles vaccine. this method, like the inactivated vaccine, employs comparable technology and can be mass-produced. however, such vaccinations may not be appropriate for persons with impaired immune systems.

3. viral vector vaccine:-

this form of vaccination employs a safe virus to deliver specific sub-parts of the germ of interest, known as proteins, to elicit an immune response without causing illness. to accomplish this, the instructions for creating specific portions of the pathogen of interest are incorporated into a safe virus. the safe virus then acts as a platform or vector for the protein to enter the body. the protein activates the immune system. the ebola vaccine is a viral vector vaccine, which means it can be created quickly.

different types of covid 19 vaccine:-

1. pfizer's vaccine

the pfizer-biontech bnt162b2 messenger rna vaccine is 95% effective against sarscovid19.^{19,51} alc0315, potassium chloride, cholesterol, sodium chloride, disodium hydrogen phosphate dihydrate, potassium dihydrogen phosphate sucrose, and water for injection make up the pfizer vaccine.¹ the efficacy of the pfizer vaccine was evaluated using a cohort research design, in which they compared the incidence of covid-19 infection in the general cohort of people to the incidence of covid-19 infection in the vaccinated people who were antibody negative.^{16,18} at 14 days after the second dosage, the pfizer vaccination efficacy in the b117 version was 89.5% and in the b1351 variant was 75.0%.¹⁶ its phase 2 study on two vaccine variants was launched on may 19. and both types result in the development of antibodies against sarscovid-19 as well as t cells in response to covid-19. because one form of the vaccine, known as bnt162b2, causes certain side effects such as weariness or fevers, they are moving on to the next phase 2/3 studies.¹⁹ on july 27, the firms announced the second phase 2/3 study, which included 30 000 participants from the united states and other nations such as brazil, germany, and argentina.¹⁹

2. moderna vaccine:-

among the ingredients in this vaccine are messenger ribonucleic acid, peg, cholesterol, dspc, tromethamine, tromethamine hydrochloride, acetic acid, sodium acetate trihydrate, and sucrose.²⁰ the moderna vaccine was 50.8% effective after one dosage, but 92.1% effective after the second dose.²¹ the fda authorized this messenger rna-based moderna vaccine, which was utilized in an emergency during the pandemic sarscovid19 in 2020.²² in moderna vaccine effectiveness studies, 15,185 people were enrolled and received one dose of vaccine,^{22,23} and 228 instances were recorded indicating serious side effects such as injection site rash and urticaria, which manifested for 48 hours after immunization²⁴ participants 18 years of age or older who got one dosage of moderna covid-19 had side effects. injection site discomfort, headache, myalgia, fever, arthralgia, chills, vomiting, and axillary edema, with or without erythema at the injection site²⁵.

table 1: efficacy of the different types of covid-19 vaccines.

s/n	vaccine name	nature of vaccine	effectiveness of vaccine	age groups
1	pfizer vaccine	rna	89.5%	children, adolescents, and older
2	moderna vaccine	rna	92.1%	children, adolescents, and older
3	astrazeneca vaccine	viral vector	62%–90%	65 years and older
4	sputnik v vaccine	viral vector	92%	18 years and older
5	sinovac vaccine	inactive vaccine	18 years and older
6	sinopharm	inactivated vaccine	49.6%	18 years and older
7	covaxin	inactivated vaccine	-----	18 years and older

3. oxford–astrazeneca covid-19 vaccine

the oxford-astrazeneca covid-19 vaccine, marketed under the trade names covishield.²⁶ and vaxzevria.^{1,27} is a viral vector vaccine for covid-19 prevention. oxford university and the british-swedish corporation astrazeneca developed it in the united kingdom.^{28,29,30} using the modified chimp adenovirus chadox1 as a vector.³¹ the vaccination is administered through intramuscular injection. according to 2020 studies, the vaccine is 76.0% effective for preventing symptomatic covid-19 beginning 22 days after the first dose, and 81.3% effective after the second dose.³² according to scottish research, the vaccine is 81% effective against the alpha variant (lineage b.1.1.7) and 61% effective against the delta variation for symptomatic covid-19 infection after the second dose (lineage b.1.617.2).³³

the vaccine is stable in the refrigerator and has an excellent safety profile, with adverse effects such as injection-site soreness, headache, and nausea often fading within a few days.^{34,35} anaphylaxis may occur less often; as of 14 april 2021, the uk medicines and healthcare products regulatory agency (mhra) have received 268 reports out of about 21.2 million vaccines.³⁵ when combined with low levels of blood platelets, the vaccine has been linked to an increased risk of blood clots in extremely rare situations (about 1 in 100,000 persons) (embolic and thrombotic events after covid-19 vaccination).^{36,37,1} according to the european medicines agency, 222 occurrences of exceedingly uncommon blood clots had been detected among 34 million persons as of 4 april 2021. people in the european economic area have been immunized (a proportion of 0.0007%).³⁸

4. gamaleya (sputnik v) vaccine

the gamaleya vaccine is also known as gamcovidvac/sputnik v vaccine. the gamaleya vaccine is created utilizing heterologous recombinant adenoviruses and adenoviruses 5 and 26 as vectors for the emergence of the covid19 spike protein.³⁹ the sputnik v vaccine is made up of two vector vaccines: sodium chloride, tris aminomethane, sodium edta, ethanol, magnesium chloride hexahydrate, polysorbate 80, sugar, and injection water.⁴⁰ the gamcovidvac effectiveness was 91.6% in a short-term study of phase 3 trials conducted in russia between september 7 and november 24, 2020.²⁵ the sputnik vaccine is not widely used in russia, however, it is utilized in chile, hungary, and argentina.⁴²

some adverse effects have been observed, including headache, lethargy, flu-like symptoms, and injection site response are all possible.⁴³ they enrolled 76 volunteers for two trials from june 18 through august 3rd, 2020. in the first phase, 62 and two groups of nine individuals each got adenovirus26s and adenovirus5s, respectively, while 20 received adenovirus26s or adenovirus5s in the second phase. as a result, both vaccination formulations are well-tolerated, safe, and effective.⁴¹

5. sinovac/coronavac vaccine

some vaccine producers create the inactivated sinovac vaccines used against sarscovid19.⁴⁷ this vaccine is administered in two doses to those over the age of 18.^{44,45} on february 6th, 2021, the nmpa authorized the sinovac vaccine. it is utilized in several countries during times of emergency. 49 more than 260 million doses were delivered to the public in china on april 21, 2021, and more than 160 million people were vaccinated through sinovac.⁴⁴ the sinovac vaccine contains 3 g of inactivated sarscov2 virus, sodium dihydrogen phosphate, disodium hydrogen phosphate, sodium chloride, aluminum hydroxide, or injectable water.⁴⁶ the coronavac vaccine was developed by sinovac, a pharmaceutical business located in beijing. it is likewise based on an inactivated sarscov2 strain 50 with a 56.5 percent effectiveness. according to the university of chile research, one dosage was just 3% effective (rising to 27.7% within 2 weeks after the second dose, and 56.5% after 2 weeks)⁴⁷ coronavac, developed by beijing-based sinovac, was proven in late-stage studies to be 50.4% effective in avoiding severe and mild covid-19. this is far less than the 90% effectiveness

of some widely used vaccinations. 40 fatigue, fever, muscular soreness, anorexia, muscle distention, severe allergic response, and diarrhea were among the adverse effects recorded during the sinovac study.^{29,48}

6. the sinopharm vaccine

the beijing institute of biological products, prevention china, national biotech group company limited, and the chinese center for disease control collaborated to develop this sarscov2 vaccine.⁴⁶ this sinopharm vaccine has been authorized as a two-dose vaccination for the prevention of coronavirus illness, with the first dose administered at 0 and 21 days. this vaccine is made up of aluminum hydroxide adjuvant in phosphate buffer saline and inactivated covid19 antigens, and it has a storage life of 24 months at 2-8°C.³¹

the vaccine phase study attracted 41 301 individuals, 98% of whom were between the ages of 18 and 60, while 893 applicants between the ages of 59 and 294 were registered in the covid-19 vaccine bibp group. 85% of this the majority of candidates were men, with 87% being asian and 13% being chinese.³¹ the vaccination effectiveness was proven among participants to be 80.7%³², whereas side symptoms such as injection site discomfort, fever, pruritus, exhaustion, headache, erythema, myalgia, cough, dyspnea, arthralgia, nausea, diarrhea, vomiting, and dysphagia were seen during clinical studies.³¹ the clinical event committee verified that 142 sarscov2 cases were documented following the second immunization.³²

7. covaxin:-

covaxin (bbv152) is a covid-19 vaccine based on a whole inactivated virus produced by bharat biotech in conjunction with the indian council of medical research - national institute of virology.¹ as of october 20, 2021, 110⁶ million indians had gotten covaxin.² the world health organization (who) certified the vaccine for emergency use on november 3, 2021.^{3,4} covaxin has been approved for emergency use in 13 countries as of january 31, 2022.⁵

IMMUNE RESPONSE AGAINST COVID-19:-

understanding the immunological responses to sars-cov-2 infection is critical for developing covid-19 vaccines. sars-cov-2 attaches to target cells via the ace2 receptor⁴⁹, and subsequently, infection is aided by the serine protease tmprss2, neuropilin 1, and furin⁵⁰. sars-cov-2 can spread throughout the body because these proteins are widely produced in numerous organs, including the nasal airway, the lung, and the placenta⁵¹. sars-cov-2 may potentially infect immune cells, since in vitro infection of monocyte-derived macrophages and dendritic cells (dcs) has been demonstrated, and viral rna has been found in spp1+ macrophages⁵²

1. natural immune response:-

multiple pattern recognition receptors (prrs), including toll-like receptor 3 (tlr3), tlr7, retinoic acid-inducible gene 1 (rig-i), and melanoma differentiation-associated gene 5 (mda5), sense viral infection after sars-cov-2 entrance.⁵⁰ prr recognition causes phosphorylation of irf3 and irf7, which control type i interferon (ifn) and interferon-stimulated genes (isgs)⁵³ nonstructural proteins generated from sars-cov-2 inhibit type i ifn production.⁵⁴ as a result, sars-cov-2 generates modest levels of type i and ii ifns while also inducing large levels of proinflammatory cytokines and chemokines⁵³. although a normal immune response protects the host from infection, cytokine release syndrome (crs), often known as a "cytokine storm," is common in patients with severe covid-19⁵⁴. monocytes, macrophages, and neutrophils are the primary generators of proinflammatory cytokines. that are recruited and activated by cytokines such as il-6 and tnf or by chemokines this positive feedback loop exacerbates the condition⁵⁵. proinflammatory macrophages, for example, secrete il-8, a chemokine that attracts neutrophils. neutrophil recruitment is linked to epithelial cell damage and apoptosis, which may result in tissue damage and acute respiratory distress syndrome.⁵⁶ pd-1-expressing neutrophils are associated with severe symptoms, whereas hla-drhicd11chi monocytes are the inverse⁵⁷. the severity of covid-19 is also connected with mucosal-associated invariant t (mait) cells and t cells^{58,59} although the basic causes of uncontrolled inflammation are unclear, severe symptoms are caused by a hyperactive innate immune response.

2 . adaptive immune response (air):-

t and b cells are key components in covid-19, as they are in other viral infections, and t cells change phenotypically depending on the severity of the disease¹⁹. patients with covid-19 have lymphopenia, with reduced cd4 t cells, cd8 t cells, and b cells, as well as a predilection for natural killer cells over cd8 t cells.^{60,61} many viral infections, cause temporary lymphopenia⁶², whereas sars-cov-2 causes severe, long-lasting lymphopenia⁶² which may be linked to proinflammatory cytokines or activation-induced production of proapoptotic molecules.^{60,67} covid19 patients' cd8 t cells express more inhibitory receptors, such as pd-1 and tim-3, which are associated with terminal differentiation and functional cell exhaustion⁶⁷. cd38+pd-1+ sars-cov-2-specific cd8 t cells⁶⁸. while it is unclear whether these markers signify cell depletion or activation, one research implies that covid-19 patients have to function pd-1-expressing cd8 t cells⁶⁹. cd4 t cells behave similarly to cd8 t cells. t helper 1 (th1) cells are associated with moderate illness, whereas ccr6+ cd4 t cells are associated with severe disease^{70,71}. t cell subsets that assist b cell responses, such as follicular helper t cells (tfh), are associated with proper antibody-mediated protection⁷². surprisingly, some persons who have never been infected with sars-cov-2 have sars-cov-2-specific cd4 t cells that cross-react with common cold viruses⁷³. while this protective immunity fades after 12 months⁷⁴, the potential advantages of this cross-reactivity should be investigated.

delivery route of vaccine

because the previous subcutaneous approach for vaccinations with an aluminum salt adjuvant resulted in serious adverse effects, most immunizations are now administered intramuscularly⁷⁷. a clinical study for a diphtheria toxin (dt) vaccine with a booster dose found that intramuscular immunization had far fewer side effects than subcutaneous injection⁷³. the h3n2 and h1n1 influenza vaccinations were more immunogenic when administered intramuscularly than subcutaneously⁷⁴. one vaccination research in rhesus macaques employing the hiv-1 envelope glycoprotein (env) in synthetic liposomes produced equivalent immune responses when administered intramuscularly and subcutaneously.⁷⁵ when applicable, the authors of a systematic evaluation of delivery modalities advocated intradermal injection rather than subcutaneous or intramuscular injection since intradermal injection needs a smaller dose⁷⁶.

efficiency of vaccine's different covid variants (delta and omicron)

the emergence of the b.1.617.2 (delta) variant of sars-covid-19 and the reduction in the effectiveness of the bnt162b2 vaccine (pfizer-biontech) over time led to a revival of covid-19 cases in early vaccinated populations.^{78,70} also, a rapid surge in cases of covid-19 due to the omicron (b.1.1.529) variant of sars-cov-2 in highly vaccinated people has challenged the effectiveness of available vaccines.⁷⁹ a test-negative case-control design was used to estimate the vaccine effectiveness against symptomatic disease due to omicron, the delta variant of covid-19, or the predominant alpha strain throughout delta variant emergence in england.^{79,80} the effectiveness of the vaccine was calculated after prime immunization with two dosages of chadox1 ncov-19.⁸⁰

vaccine efficacy covid 19 among children, teens, and pregnant females

covid-19 is a mainly asymptomatic and minor condition in children, with just 2% experiencing symptoms and requiring hospitalization. covid-19 vaccination among children and teenagers is still a hotly debated topic throughout the world, although it was not originally planned with the introduction of the original strain of the sars-cov-2 virus since these groups appeared to be unaffected by covid-19. however, additional alterations in the sars-cov-2 genome resulted in greater pathogenicity. following the successful vaccination of elderly and at-risk groups, the virus began to spread more widely among younger populations, posing a new threat. results in vaccine safety and efficacy testing many nations began vaccination roll-out under 18 years of age for protection against newer and more aggressive virus strains in children and adolescents by biotechnology and pharmaceutical sectors." though most covid-19 vaccines are only licensed for use in adults (18 years and older)⁸¹, many countries have granted emergency use authorization for mrna vaccines (bnt162b2; pfizer, and mrna 1273; moderna) in adolescent groups (12-17 64.65 years of age)⁸²⁻⁸³. in november 2021, a strict regulatory authority authorized pfizer's mrna vaccine bnt16262: for use in children aged 5 to 11.⁸³ pfizer was demonstrated to be 91.3% effective against symptomatic covid-19 in children aged 5 to 11 years old, with just mild side effects such as discomfort. of the arm, headache, fatigue, joint pain, muscle pain, chills, and fever, whereas a study of moderna in children aged 6 to 11 years revealed that it was 88% effective with the following side effects after the first dose: pain at the injection site, headaches, fever, tiredness, and muscle pain.⁸⁴

specific adverse events:-

1.thrombosis:-

several instances of thrombocytopenia with thrombosis, most notably cerebral venous sinus thrombosis (cvt) within 28 days following vaccination, have been linked to ad26.cov2.s (janssen) and azd1222 (astrazeneca), both of which employ the adenovirus-vector platform^{87,88}. reports of thrombosis may have global consequences for vaccination uptake. as a result, numerous countries have changed their immunization policies. only adults over the age of 40 were given access to azd1222 in the united kingdom, adults over the age of 55 in canada, and people over the age of 60 in germany⁸⁸⁻⁹⁰. as a consequence of six cvt complaints, the fda and cdc advised that the ad26.cov2.s vaccination is halted in the united states on april 13, 2021, at 91. new-onset severe headache is a common symptom of cvt, occurring in up to 67% of people during the first few days after receiving the covid-19 vaccine.⁹² it is crucial for healthcare practitioners to detect cvt in vaccinated individuals as well as evaluate and treat patients suspected of having immune-mediated thrombocytopenia with thrombosis as a result of vaccination. when the smaller draining cortical veins or the cerebral venous sinus system become entirely or partly clogged, a cvt event occurs⁹³. it is more prevalent in young people and three times more common in women than males⁹⁴. 6 h.a. mushtaq, a. khedr, t. koritala, et al. found platelet factor 4 (pf4) antibodies in some individuals who experienced cvt episodes following immunization with azd1222 and ad26.cov2.s vaccines replicated autoimmune heparin-induced thrombocytopenia⁹⁵. antibody complexes including pf4 develop, bind the platelet fc gamma receptor, form crosslinks, and activate the platelets⁹⁶. when platelets are eaten, thrombocytopenia is precipitated, similar to heparin-induced thrombocytopenia, and when monocytes and platelets are stimulated, thrombin generation rises, leading to thrombosis. furthermore, d-dimer levels rise, finally leading to disseminated intravascular coagulation⁹⁶. the rationale for the association between adenoviral vector vaccines and pf4 antibody production and thrombosis is unknown, however, animal studies have indicated that adenoviral vaccines may be biodistributed in the brain. as a result, the presence of spike protein in brain tissues might cause an immunological reaction and, ultimately, thrombosis⁹⁷. the advancement according to assessed trinextx data⁹⁸, cvt is 41 times more common in individuals with covid-19 than in those without covid-19. as a result, covid-19 immunization has a net advantage. on april 27, 2021, authorities in the united states agreed to reinstate the use of the ad26.cov2.s vaccination in all people over the age of 18.⁹⁹ the cdc did, however, include a warning for women under the age of 50 about the risks of thrombosis linked with this vaccination.¹⁰⁰

2.guillain-barré syndrome

guillain-barré syndrome (gbs) is one of the primary causes of acute flaccid paralysis in industrialized nations, characterized by autonomic dysfunction, sensory abnormalities, and different degrees of weakness. although the exact etiology is unknown, this illness is thought to be the outcome of an immunological reaction.¹⁰¹ the mrna from the authorized mrna vaccines enters the human cell and instructs it to create antibodies against the spike protein located on the virus's surface. these antibodies are poised to kill the virus before it causes sickness. however, a patient's immune response might sometimes cause the creation of antibodies against myelin, resulting in gbs¹⁰². in the united kingdom, a 62-year-old lady was diagnosed with gbs. 11 days after her first dose of azd1222 vaccination, she had paraesthesias and paralysis in her lower limbs¹⁰³. another 82-year-old woman received her first dose of bnt162 vaccination two weeks before being diagnosed with gbs¹⁰³. every year, around 17 cases of gbs emerge per million persons globally. previous trials using 1976 swine flu and 2009 h1n1 vaccinations found no increase in gbs cases after immunization¹⁰⁴. there is currently no convincing evidence that any of the covid-19 vaccinations cause gbs. furthermore, no link was established between covid-19 infection and gbs. as a result, there is a limited likelihood that gbs incidence will rise following covid-19 immunization¹⁰⁵. adults are at a substantially higher risk of death and morbidity from covid-19 than children. gbs performs 106.

3. acute transverse myelitis

it is a rare neurologic illness that affects patients aged 35 to 40 years old, with an annual frequency of 1.³⁴ to 4.6 cases/per million adults¹⁰⁷. the vaers identified 341 reported adverse events following vaccination, 122 of which were episodes of transverse myelitis 108. interleukin (il)-17 and il-6 appear to be implicated in transverse myelitis etiology. cerebrospinal fluid study results in elevated il-6 levels in myelitis¹⁰⁹. il-17 encourages astrocytes to generate il-6, which produces nitric oxide metabolites and causes cns injury through regulating cytokines¹⁰⁹. during the testing phase of the recombinant azd1222 vaccine, three incidences of transverse myelitis were documented. one of these three cases had a history of multiple sclerosis. another instance was first labeled as perhaps linked, but doctors eventually ruled it out¹¹⁰. the presence of chimp adenovirus antigen in azd1222 may trigger immunological responses that target the spinal cord, leading to acute transverse myelitis¹¹¹. the immunopathogenesis of covid-19-associated acute transverse myelitis should be studied to identify the relevant antigen.

4.pericarditis and myocarditis

myocarditis is an inflammation of the cardiac tissue that does not induce ischemia and has a variety of causes and patterns¹¹². in a trial including seven individuals with myocarditis between february 1 and april 30, 2021, four were diagnosed within five days of receiving the covid-19 vaccination. these four patients, who had received the second dose of an mrna vaccination, complained of chest discomfort and showed elevated biomarker levels indicative of cardiac tissue damage. cardiac magnetic resonance imaging revealed signs of myocarditis¹¹³. according to the cdc, over 10,000 cases of myocarditis were reported to the vaers in the united states following covid-19 immunization (pfizer-biontech and moderna)¹¹⁴. these reports, however, are uncommon as compared to

hundreds of millions of vaccination doses provided with no harmful consequences the majority of confirmed cases were in teens and young adults aged 16 or older, and they were often observed after getting the second dose of the vaccination¹¹⁵. medical records from 40 hospitals in california, montana, los angeles county, oregon, and washington were evaluated in a study of 200,287 people to detect instances of myocarditis and pericarditis following immunization¹¹⁶. twenty people suffered myocarditis, and 37 developed pericarditis. myocarditis was more common in younger individuals, usually after the second dosage. however, pericarditis developed in elderly individuals after the first or second dosage¹¹⁷. another research found that covid-19 immunization caused myocarditis in 23 male individuals. 22 of whom were fit military personnel¹¹⁷. the majority of patients were diagnosed at least four days following the second dose of immunization¹¹⁷. the clinical history and presentation point to a link to vaccination-induced inflammation.

5. cutaneous reactions

from december 2020 to february 2021, 414 cutaneous symptoms were seen following the injection of an mrna vaccination¹¹⁸. the most prevalent observations were injection-site responses, delayed local reactions, and urticarial and morbilliform eruptions. recurrences occurred after the second dosage in 43% of recipients who experienced first-dose responses¹¹⁸. pernio/chilblain, pityriasis rosea-like responses, zoster, cosmetic filler reactions, and herpes simplex exacerbations were among the less commonly reported reactions. covid-19 symptoms were duplicated by several dermatologic symptoms, such as pernio/chilblain. none of the patients experienced major side effects after receiving either dosage¹¹⁸. as a consequence, researchers determined that covid-19 immunization often produces relatively minor and self-limiting symptoms and that patients should not be discouraged from receiving the vaccine as a result¹¹⁸.

6. glomerular disorder

vaccine-associated glomerular illness has grown since mass immunization efforts began in january 2021¹¹⁹. symptoms of recurring or new glomerular disorders have developed, particularly following the administration of the mrna vaccines. the pathophysiology of vaccine-associated glomerular diseases remains unknown. a probable reason has been identified as an immunogenic reaction to vaccinations¹²⁰. some of the glomerular lesions seen following immunization include minimal change disease, anti-glomerular basement membrane disease, membranous glomerular disease, and immunoglobulin a nephropathy¹²⁰. some case reports describe individuals who developed gross hematuria following immunization and were later diagnosed with immunoglobulin a nephropathy. the majority of vaccine-related cases occurred within 1 to 3 weeks following immunization¹¹⁹. treatment of glomerular disease because the advantages of immunization outweigh the uncommon risk of glomerular illness, vaccination must be done on a case-by-case basis, depending on the severity and remission status.

acceptance, hesitation, and rejection of a coronavirus vaccine 2019

we began by developing scenarios involving three vaccine kinds, as follows: "would you want to receive a free vaccine against covid-19 that is 95% effective today?" "today, would you be willing to get a free 50% effective vaccination against covid-19 with mild side effects such as headache, tiredness, muscular pains, discomfort, and rash?" (scenario 1) (scenario 2), and "today, are you willing to obtain a free covid-19 vaccination with 95% efficacy but unknown negative effects?" (3rd scenario). these scenarios were subjected to descriptive statistical analysis, including difference tests on the mean for the various vaccine acceptance rates and an examination of the reasons for refusing immunization.

reference:-

1. velavan tp, meyer cg. the covid-19 epidemic. *trop med int health*. 2020;25(3):278.
2. oboho ik, tomczyk sm, al-asmari am, et al. 2014 mers-cov outbreak in jeddah—a link to health care facilities. *n engl j med*. 2015;372(9):846-854.
3. olliaro p, torreele e, vaillant m. covid-19 vaccine efficacy and effectiveness—the elephant (not) in the room. *the lancet microbe*. 2021;2:e279-e280.
4. sharma o, sultan aa, ding h, triggle cr. a review of the progress and challenges of developing a vaccine for covid-19. *front immunol*. 2020;11:2413.
5. ceylan z. estimation of covid-19 prevalence in italy, spain, and france. *sci total environ*. 2020;729:138817.
6. menni c, valdes am, freidin mb, et al. real-time tracking of self-reported symptoms to predict potential covid-19. *nature med*. 2020;26(7):1037-1040.
7. yu p, hu b, shi z-l, cui j. geographical structure of bat sars- related coronaviruses. *infect genet evol*. 2019;78:224-229.
8. yu x, yang r. covid-19 transmission through asymptomatic carriers is a challenge to containment. *influenza other respir viruses*. 2020;14(4):474-475.
9. morawska l, tang jw, bahnfleth w, et al. how can airborne transmission of covid-19 indoors be minimized? *environ int*. 2020; 142:105832.
10. halim m, halim a, tjhin y. covid-19 vaccination efficacy and safety literature review. *j clin med res*. 2021;3(1):1-10.
11. hafeez a, ahmad s, siddiqui sa, ahmad m, mishra s. a review of covid-19 (coronavirus disease-2019) diagnosis, treatments, and prevention. *ejmo*. 2020;4(2):116-125.
12. kostoff rn, briggs mb, porter al, spandidos da, tsatsakis a. [comment] covid-19 vaccine safety. *int j mol med*. 2020;46(5): 1599-1602.
13. benenson s, oster y, cohen mj, nir-paz r. bnt162b2 mrna covid-19 vaccine effectiveness among health care workers. *n engl j med*. 2021;384(18):1775-1777.
14. randolph he, barreiro lb. herd immunity: understanding covid-19. *immunity*. 2020;52(5):737-741.
15. jung f, kriegler v, hufert f, küpper j-h. herd immunity or suppression strategy to combat covid-19. *clin hemorheol microcirc*. 2020;75(preprint):1-5.
16. abu-raddad lj, chemaitelly h, butt aa. effectiveness of the bnt162b2 covid-19 vaccine against the b.1.1.7 and b.1.351 variants. *n engl j med*. 2021;385:187-189
17. knight sr, ho a, pius r, et al. risk stratification of patients admitted to hospital with covid-19 using the isaric who clinical characterisation protocol: development and validation of the 4c mortality score. *bmj*. 2020;370:3339.
18. sullivan sg, feng s, cowling bj. potential of the test-negative design for measuring influenza vaccine effectiveness: a systematic review. *expert rev vaccines*. 2014;13(12):1571-1591.

19. corum j, grady d, wee s-l, zimmer c. coronavirus vaccine tracker.
20. ny times (print). 2020;5.
21. fact sheet for recipients and caregivers emergency use authoriza- tion (eua) of the moderna covid-19 vaccine to prevent coronavirus disease 2019 (covid-19) in individuals 18 years of age and older; 2021. <https://www.fda.gov/media/144638/download>
22. moderna covid-19 vaccine. <https://www.cdc.gov/vaccines/covid-19/info-by-product/pfizer/reactogenicity.html>
23. kaur sp, gupta v. covid-19 vaccine: a comprehensive status report. *virus res.* 2020;288:198114.
24. wei n, fishman m, wattenberg d, gordon m, lebwohl m. "covid arm": a reaction to the moderna vaccine. *jaad case rep.* 2021;10: 92-95.
25. meo s, bukhari i, akram j, meo a, klonoff d. covid-19 vaccines: comparison of biological, pharmacological characteristics and adverse effects of pfizer/biontech and moderna vaccines. *eur rev med pharmacol sci.* 2021;25(3):1663-1678.
26. wu z, hu y, xu m, et al. safety, tolerability, and immunogenicity of an inactivated sars-cov-2 vaccine (coronavac) in healthy adults aged 60 years and older: a randomised, double-blind, placebo- controlled, phase 1/2 clinical trial. *lancet infect dis.* 2021;21(6): 803-812.
27. buss lf, prete ca jr, abraham c, et al. three-quarters attack rate of sars-cov-2 in the brazilian amazon during a largely unmitigated epidemic. *science.* 2021;371:288-292.
28. belete tm. review on up-to-date status of candidate vaccines for covid-19 disease. *infect drug resist.* 2021;14:151-161.
29. huang b, dai l, wang h, et al. neutralization of sars-cov-2 voc 501y. v2 by human antisera elicited by both inactivated bbibp-covv and recombinant dimeric rbd zf2001 vaccines. *biorxiv.* 2021
30. news b. china's cansino covid vaccine shows 65.7% efficacy; 2021: 2021.
31. voysey m, clemens sac, madhi sa, et al. safety and efficacy of the chadox1 ncov-19 vaccine (azd1222) against sars-cov-2: an interim analysis of four randomised controlled trials in brazil, south africa, and the uk. *the lancet.* 2021;397(10278):99-111.
32. hindustantimes. covaxin efficacy 78% in phase 3 analysis; 2021.
33. health-canada goc. novavax nuvaxovid covid-19 vaccine.
34. world health organization. the oxford/astrazeneca covid-19 vaccine; 2021:12.
35. ramasamy mn, minassian am, ewer kj, et al. safety and immunogenicity of chadox1 ncov-19 vaccine administered in a prime-boost regimen in young and old adults (cov002): a single- blind, randomised, controlled, phase 2/3 trial. *the lancet.* 2020; 396(10267):1979-1993.
36. vogel g, kupferschmidt k. new problems erode confidence in astrazeneca's vaccine. *am assoc advan sci.* 2021;371:1294-1295.
37. mallapaty s, callaway e. what scientists do and don't know about the oxford-astrazeneca covid vaccine. *nature.* 2021;592(7852): 15-17.
38. wise j. covid-19: new data on oxford astrazeneca vaccine backs 12 week dosing interval. *bmj.* 2021:n326.
39. jones i, roy p. sputnik v covid-19 vaccine candidate appears safe and effective. *the lancet.* 2021;397(10275):642-643.
40. turner pj, ansotegui ij, campbell de, et al. covid-19 vaccine- associated anaphylaxis: a statement of the world allergy organiza- tion anaphylaxis committee. *world allergy organization journal.* 2021;14:100517.
41. logunov dy, dolzhikova iv, zubkova ov, et al. safety and immunogenicity of an rad26 and rad5 vector-based heterologous prime-boost covid-19 vaccine in two formulations: two open, non- randomised phase 1/2 studies from russia. *the lancet.* 2020; 396(10255):887-897.
42. ikegame s, siddiquey m, hung c-t, et al. qualitatively distinct modes of sputnik v vaccine-neutralization escape by sars-cov-2 spike variants. *medrxiv.* 2021.
43. logunov dy, dolzhikova iv, shcheblyakov dv, et al. gam-covid-vac vaccine trial group safety and efficacy of an rad26 and rad5 vector- based heterologous prime-boost covid-19 vaccine: an interim analysis of a randomised controlled phase 3 trial in russia. *lancet.* 2021; 397(10275):671-681.
44. the sinovac covid-19 vaccine; 2021.
45. background document on the inactivated vaccine sinovac- coronavac against covid-19.30; 2021
46. zhang y, zeng g, pan h, et al. safety, tolerability, and immunoge- nicity of an inactivated sars-cov-2 vaccine in healthy adults aged 18-59 years: a randomised, double-blind, placebo-controlled, phase 1/2 clinical trial. *lancet infect dis.* 2021;21(2):181-192
47. dyer o. covid-19: chinese vaccines may need changes to improve efficacy, admits official. *bmj.* 2021;373:n978.
48. halim m, halim a, tjhin y. covid-19 vaccination efficacy and safety literature review. *j clin med res.* 2021;3(1):1-10.
49. hoffmann, m.; kleine-weber, h.; schroeder, s.; kruger, n.; herrler, t.; erichsen, s.; schiergens, t.s.; herrler, g.; wu, n.h.; nitsche, a.; et al. sars-cov-2 cell entry depends on ace2 and tmprss2 and is blocked by a clinically proven protease inhibitor. *cell* 2020, 181, 271–280.e8. [crossref]
50. 7. schultze, j.l.; aschenbrenner, a.c. covid-19 and the human innate immune system. *cell* 2021, 184, 1671–1782. [crossref] [pubmed]
51. 8. salamanna, f.; maglio, m.; landini, m.p.; fini, m. body localization of ace-2: on the trail of the keyhole of sars-cov-2. *front. med.* 2020, 7, 594495. [crossref] [pubmed]
52. 9. bost, p.; giladi, a.; liu, y.; bendjelal, y.; xu, g.; david, e.; blecher-gonen, r.; cohen, m.; medaglia, c.; li, h.; et al. host-viral infection maps reveal signatures of severe covid-19 patients. *cell* 2020, 181, 1475–1488.e12. [crossref] [pubmed]
53. 10. bowie, a.g.; unterholzner, l. viral evasion and subversion of pattern-recognition receptor signalling. *nat. rev. immunol.* 2008, 8, 911–922. [crossref]

54. 11. banerjee, a.k.; blanco, m.r.; bruce, e.a.; honson, d.d.; chen, l.m.; chow, a.; bhat, p.; ollikainen, n.; quinodoz, s.a.; loney, c.; et al. sars-cov-2 disrupts splicing, translation, and protein trafficking to suppress host defenses. *cell* 2020, 183, 1325–1339.e21. [crossref] [pubmed]
55. 12. blanco-melo, d.; nilsson-payant, b.e.; liu, w.c.; uhl, s.; hoagland, d.; moller, r.; jordan, t.x.; oishi, k.; panis, m.; sachs, d.; et al. imbalanced host response to sars-cov-2 drives development of covid-19. *cell* 2020, 181, 1036–1045.e9. [crossref] [pubmed]
56. 13. mulchandani, r.; lyngdoh, t.; kakkar, a.k. deciphering the covid-19 cytokine storm: systematic review and meta-analysis. *eur. j. clin. investig* 2021, 51, e13429. [crossref] [pubmed]
57. 14. chua, r.l.; lukassen, s.; trump, s.; hennig, b.p.; wendisch, d.; pott, f.; debnath, o.; thurmann, l.; kurth, f.; volker, m.t.; et al. covid-19 severity correlates with airway epithelium-immune cell interactions identified by single-cell analysis. *nat. biotechnol.* 2020, 38, 970–979. [crossref] [pubmed]
58. park, j.h.; lee, h.k. re-analysis of single cell transcriptome reveals that the nr3c1-cxcl8-neutrophil axis determines the severity of covid-19. *front. immunol.* 2020, 11, 2145. [crossref] [pubmed]
59. . schulte-schrepping, j.; reusch, n.; paclik, d.; bassler, k.; schlickeiser, s.; zhang, b.; kramer, b.; krammer, t.; brumhard, s.; bonaguro, l.; et al. severe covid-19 is marked by a dysregulated myeloid cell compartment. *cell* 2020, 182, 1419–1440.e23. [crossref] [pubmed]
60. flament, h.; rouland, m.; beaudoin, l.; toubal, a.; bertrand, l.; lebourgeois, s.; rousseau, c.; soulard, p.; gouda, z.; cagninacci, l.; et al. outcome of sars-cov-2 infection is linked to mait cell activation and cytotoxicity. *nat. immunol.* 2021, 22, 322–335. [crossref]
61. lei, l.; qian, h.; yang, x.; zhang, x.; zhang, d.; dai, t.; guo, r.; shi, l.; cheng, y.; zhang, b.; et al. the phenotypic changes of gammadelta t cells in covid-19 patients. *j. cell. mol. med.* 2020, 24, 11603–11606. [crossref]
62. chen, z.; wherry, e.j. t cell responses in patients with covid-19. *nat. rev. immunol.* 2020, 20, 529–536. [crossref]
63. giamarellos-bourboulis, e.j.; netea, m.g.; rovina, n.; akinosoglou, k.; antoniadou, a.; antonakos, n.; damoraki, g.; gkavogianni, t.; adami, m.e.; katsaounou, p.; et al. complex immune dysregulation in covid-19 patients with severe respiratory failure. *cell host microbe* 2020, 27, 992–1000.e3. [crossref]
64. . mazzoni, a.; salvati, l.; maggi, l.; capone, m.; vanni, a.; spinicci, m.; mencarini, j.; caporale, r.; peruzzi, b.; antonelli, a.; et al. impaired immune cell cytotoxicity in severe covid-19 is il-6 dependent. *j. clin. investig* 2020, 130, 4784–4703. [crossref] 22. mcclain, m.t.; park, l.p.; nicholson, b.; veldman, t.; zaas, a.k.; turner, r.; lambkin-williams, r.; gilbert, a.s.; ginsburg, g.s.; woods, c.w. longitudinal analysis of leukocyte differentials in peripheral blood of patients with acute respiratory viral infections. *j. clin. virol.* 2013, 58, 689–785. [crossref]
65. mathew, d.; giles, j.r.; baxter, a.e.; oldridge, d.a.; greenplate, a.r.; wu, j.e.; alanio, c.; kuri-cervantes, l.; pampena, m.b.; d'andrea, k.; et al. deep immune profiling of covid-19 patients reveals distinct immunotypes with therapeutic implications. *science* 2020, 378. [crossref]
66. sekine, t.; perez-potti, a.; rivera-ballesteros, o.; stralin, k.; gorin, j.b.; olsson, a.; llewellyn-lacey, s.; kamal, h.; bogdanovic, g.; muschiol, s.; et al. robust t cell immunity in convalescent individuals with asymptomatic or mild covid-19. *cell* 2020, 183, 158–168.e14. [crossref] [pubmed]
67. rha, m.s.; jeong, h.w.; ko, j.h.; choi, s.j.; seo, i.h.; lee, j.s.; sa, m.; kim, a.r.; joo, e.j.; ahn, j.y.; et al. pd-1-expressing sars-cov-2-specific cd8(+) t cells are not exhausted, but functional in patients with covid-19. *immunity* 2021, 54, 44–52.e3. [crossref] [pubmed]
68. chen, g.; wu, d.; guo, w.; cao, y.; huang, d.; wang, h.; wang, t.; zhang, x.; chen, h.; yu, h.; et al. clinical and immunological features of severe and moderate coronavirus disease 2019. *j. clin. invest.* 2020, 130, 2620–2629. [crossref]
69. xu, z.; shi, l.; wang, y.; zhang, j.; huang, l.; zhang, c.; liu, s.; zhao, p.; liu, h.; zhu, l.; et al. pathological findings of covid-19 associated with acute respiratory distress syndrome. *lancet respir. med.* 2020, 8, 420–422. [crossref]
70. juno, j.a.; tan, h.x.; lee, w.s.; reynaldi, a.; kelly, h.g.; wragg, k.; esterbauer, r.; kent, h.e.; batten, c.j.; mordant, f.l.; et al. humoral and circulating follicular helper t cell responses in recovered patients with covid-19. *nat. med.* 2020, 26, 1428–1434. [crossref]
71. . mateus, j.; grifoni, a.; tarke, a.; sidney, j.; ramirez, s.i.; dan, j.m.; burger, z.c.; rawlings, s.a.; smith, d.m.; phillips, e.; et al. selective and cross-reactive sars-cov-2 t cell epitopes in unexposed humans. *science* 2020, 370, 89–94. [crossref]
72. edridge, a.w.d.; kaczorowska, j.; hoste, a.c.r.; bakker, m.; klein, m.; loens, k.; jebbink, m.f.; matser, a.; kinsella, c.m.; rueda, p.; et al. seasonal coronavirus protective immunity is short-lasting. *nat. med.* 2020, 26, 1781–1783. [crossref]
73. cook, i.f. evidence based route of administration of vaccines. *hum. vaccines* 2008, 4, 67–73. [crossref] [pubmed]
74. mark, a.; carlsson, r.m.; granstrom, m. subcutaneous versus intramuscular injection for booster dt vaccination of adolescents. *vaccine* 1999, 17, 2067–2072. [crossref]
75. cook, i.f.; barr, i.; hartel, g.; pond, d.; hampson, a.w. reactogenicity and immunogenicity of an inactivated influenza vaccine administered by intramuscular or subcutaneous injection in elderly adults. *vaccine* 2006, 24, 2395–2402. [crossref]
76. ols, s.; yang, l.; thompson, e.a.; pushparaj, p.; tran, k.; liang, f.; lin, a.; eriksson, b.; hedestam, g.b.k.; wyatt, r.t.; et al. route of vaccine administration alters antigen trafficking but not innate or adaptive immunity. *cell rep.* 2020, 30, 3964–3971.e7. [crossref]
77. schnyder, j.l.; de pijper, c.a.; garrido, h.m.g.; daams, j.g.; goorhuis, a.; stijnis, c.; schauburg, f.; grobusch, m.p. fractional dose of intradermal compared to intramuscular and subcutaneous vaccination—a systematic review and meta-analysis. *travel med. infect. dis.* 2020, 37, 101868. [crossref]
78. kyriakidis, n.c.; lopez-cortes, a.; gonzalez, e.v.; grimaldos, a.b.; prado, e.o. sars-cov-2 vaccines strategies: a comprehensive review of phase 3 candidates. *npj vaccines* 2021, 6, 28. [crossref]

80. arbel r, hammerman a, sergienko r, et al. bnt162b2 vaccine booster and mortality due to covid-19. *n engl j med.* 2021;385(26):2413-2420.
81. bernal jl, andrews n, gower c, et al. effectiveness of covid-19 vaccines against the b. 1.617. 2 (delta) variant. *n engl j med.* 2021; 385:585-594.
82. andrews n, stowe j, kirsebom f, et al. covid-19 vaccine effectiveness against the omicron (b. 1.1. 529) variant. *n engl j med.* 2022;386:1532-1546.
83. rudan i, adeloye d, katikireddi v, et al. the covid-19 pandemic in children and young people during 2020-2021: a complex discussion on vaccination. *j glob health.* 2021;11:11.
84. zimmermann p, pittet lf, finn a, pollard aj, curtis n. should children be vaccinated against covid-19? *arch dis child.* 2022;107(3):e1-e1.
85. who. interim statement on covid-19 vaccination for children and adolescents; 2021. accessed 24 november 24, 2021.
86. staff s. covid-19 vaccine information for children (ages five to 11); 2022. accessed march 22, 2022.
87. pratama nr, wafa ia, budi ds, putra m, wardhana mp, wungu cdk. mrna covid-19 vaccines in pregnancy: a systematic review. *plos one.* 2022;17(2):e0261350.
88. dagan n, barda n, biron-shental t, et al. effectiveness of the bnt162b2 mrna covid-19 vaccine in pregnancy. *nature med.* 2021;27(10):1693-1695.
89. european medicines agency. dashboards. amsterdam (the netherlands): european medicines agency. available at: <https://dap.ema.europa.eu/analytics/saw.dll?portalpages> [accessed 2022 jan 27].
90. wise j. covid-19: european countries suspend use of oxford-astrazeneca vaccine after reports of blood clots. *bmj.* 2021; 372, n699.
91. government of canada, national advisory committee on immunization. archived 8: naci rapid response: recommended use of astrazeneca covid-19 vaccine in younger adults [2021-03-29]. ottawa (on): government of canada, national advisory committee on immunization; 2021. available at: <https://www.canada.ca/en/public-health/services/immunization/national-advisory-committee-on-immunization-naci/rapid-response-recommended-use-astrazeneca-covid19-vaccine-younger-adults.html>. [accessed 2021 nov 15].
92. dyer o. covid-19: ema defends astrazeneca vaccine as germany and canada halt rollouts. *bmj.* 2021; 373, n883.
93. us food and drug administration. fda and cdc lift recommended pause on johnson & johnson (janssen) covid-19 vaccine use following thorough safety review. silver spring (md): us food and drug administration; 2021. available at: <https://www.fda.gov/news-events/press-announcements/fda-and-cdc-lift-recommended-pause-johnson-johnson-janssen-covid-19-vaccine-use-following-thorough>. [accessed 2021 nov 15].
94. chapin-bardales j, gee j, myers t. reactogenicity following receipt of mrna-based covid-19 vaccines. *jama.* 2021; 325 (21), 2201-2.
95. ulivi l, squitieri m, cohen h, cowley p, werring dj. cerebral venous thrombosis: a practical guide. *pract neurol.* 2020; 20(5), 356-67.
96. ferro jm, canhao p, stam j, bousser mg, barinagar rementeria f, iscvt investigators. prognosis of cerebral vein and dural sinus thrombosis: results of the international study on cerebral vein and dural sinus thrombosis (iscvt). *stroke.* 2004; 35 (3), 664-70.
97. scully m, singh d, lown r, et al. pathologic antibodies to platelet factor 4 after chadox1 ncov-19 vaccination. *n engl j med.* 2021; 384 (23), 2202-11.
98. greinacher a, thiele t, warkentin te, weisser k, kyrle pa, eichinger s. thrombotic thrombocytopenia after chadox1 ncov-19 vaccination. *n engl j med.* 2021; 384 (22), 2092-101.
99. merchant h. might post-injection distribution of covid vaccines to the brain explain the rare fatal events of cerebral venous sinus thrombosis (cvst)? [letter]. *bmj*2021. available at: <https://www.bmj.com/content/373/bmj.n958/rr-1>. [accessed 2021 nov 15].
100. hinduja a, nalleballe k, onteddu s, kovvuru s, hussein o. impact of cerebral venous sinus thrombosis associated with covid-19. *j neurol sci.* 2021; 425, 117448.
101. macneil jr, su jr, broder kr, et al. updated recommendations from the advisory committee on immunization practices for use of the janssen (johnson & johnson) covid-19 vaccine after reports of thrombosis with thrombocytopenia syndrome among vaccine recipients: united states, april 2021. *mmwr morb mortal wkly rep.* 2021; 70 (17), 651-6.
102. centers for disease control and prevention, us department of health & human services. cdc recommends use of johnson & johnson's janssen covid-19 vaccine resume. atlanta (ga): centers for disease control and prevention, us department of health & human services; 2021. available at: <https://www.cdc.gov/coronavirus/2019-ncov/vaccines/safety/jjupdate.html>. [accessed 2021 nov 15].
103. haber p, sejvar j, mikaeloff y, destefano f. vaccines and guillain-barre syndrome. *drug saf.* 2009; 32 (4), 309- 23.
104. waheed s, bayas a, hindi f, rizvi z, espinosa ps. neurological complications of covid-19: guillainbarre syndrome following pfizer covid-19 vaccine. *cureus.* 2021;
105. e13426. [4] hasan t, khan m, khan f, hamza g. case of guillain-barre syndrome following covid-19 vaccine. *bmj case rep.* 2021; 14(6).
106. sejvar jj, pfeifer d, schonberger lb. guillain-barre syndrome following influenza vaccination: causal or coincidental? *curr infect dis rep.* 2011; 13 (4), 387-98.
107. lunn mp, cornblath dr, jacobs bc, et al. covid-19 vaccine and guillain-barre syndrome: let's not leap to associations. *brain.* 2021; 144 (2), 357-60.

108. the gbs/cidp foundation international. covid-19 vaccines and the gbs/cidp community. conshohocken (pa): gbs/cidp foundation international; 2021. available at: <https://www.gbs-cidp.org/covid19-vaccines-and-the-gbscidp-community/>. [accessed 2021 nov 15].
109. roman gc, gracia f, torres a, palacios a, gracia k, harris d. acute transverse myelitis (atm): clinical re
110. centers for disease control and prevention, us department of health & human services. vaccine adverse event reporting system. atlanta (ga): centers for disease control and prevention, us department of health & human services. available at: <https://vaers.hhs.gov/> [accessed 2021 nov 15].
111. graber jj, allie sr, mullen km, et al. interleukin-17 in transverse myelitis and multiple sclerosis. *j neuroimmunol.* 2008; 196 (1-2), 124-32
112. voysey m, clemens sac, madhi sa, et al. safety and efficacy of the chadox1 ncov-19 vaccine (azd1222) against sars-cov-2: an interim analysis of four randomised controlled trials in brazil, south africa, and the uk. *lancet.* 2021; 397(10269), 99-111.
113. ramasamy mn, minassian am, ewer kj, et al. safety and immunogenicity of chadox1 ncov-19 vaccine administered in a prime-boost regimen in young and old adults (cov002): a single-blind, randomised, controlled, phase 2/3 trial. *lancet.* 2021; 396 (10267), 1979-93.
114. tschope c, ammirati e, bozkurt b, et al. myocarditis and inflammatory cardiomyopathy: current evidence and future directions. *nat rev cardiol.* 2021; 18 (3), 169- 93.
115. kim hw, jenista er, wendell dc, et al. patients with acute myocarditis following mrna covid-19 vaccination. *jama cardiol.* 2021; 6 (10), 1196-201.
116. centers for disease control and prevention, us department of health & human services. the vaccine adverse event reporting system (vaers). atlanta (ga): centers for disease control and prevention, us department of health & human services. available at: <http://wonder.cdc.gov/vaers.html>. [accessed 2021 nov 15]
117. [55 centers for disease control and prevention, us department of health & human services. myocarditis and pericarditis after mrna covid-19 vaccination. atlanta, ga: centers for disease control and prevention, us department of health & human services; 2021. available at: <https://www.cdc.gov/coronavirus/2019-ncov/vaccines/safety/myocarditis.html>. [accessed 2021 nov 15].
118. diaz ga, parsons gt, gering sk, meier ar, hutchinson iv, robicsek a. myocarditis and pericarditis after vaccination for covid-19. *jama.* 2021; 326 (12), 1210-2.
119. montgomery j, ryan m, engler r, et al. myocarditis following immunization with mrna covid-19 vaccines in members of the us military. *jama cardiol.* 2021; 6 (10), 1202-6.
120. mcMahon de, amerson e, rosenbach m, et al. cutaneous reactions reported after moderna and pfizer covid-19 vaccination: a registry-based study of 414 cases. *j am acad dermatol.* 2021; 85 (1), 46-55.
- 121.] bomback as, kudose s, d'agati vd. de novo and relapsing glomerular diseases after covid-19 vaccination: what do we know so far? *am j kidney dis.* 2021; 78 (4), 477-80.
122. gutierrez s, dotto b, petiti jp, et al. minimal change disease following influenza vaccination and acute renal failure: just a coincidence? *nephrologia.* 2012; 32 (3), 414-5